Amylyx Co-CEO granted RSUs and stock options

Cohen Joshua B reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Cohen Joshua B reported acquisition or exercise transactions in this Form 4 filing.

Amylyx Pharmaceuticals Co-Chief Executive Officer Joshua B. Cohen reported equity awards consisting of 248,865 shares of common stock from a restricted stock unit grant and a stock option covering 373,295 shares. The RSUs vest in four equal annual installments starting on March 1, 2027, while 25% of the option vests on that date and the remainder vests monthly over the following 36 months, all subject to his continued service.

Insider Trade Summary

Grant/Award: 622,160 shares

Grant/Award 2 txns

Insider Cohen Joshua B

Role Co-Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	373,295	$0.00	$0.00
Grant/Award	Common Stock	248,865	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 373,295 contracts (Direct); Common Stock — 3,583,548 shares (Direct)

Footnotes (2)

1. F1. The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
2. F2. 25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AMLX Co-CEO Joshua B. Cohen report on this Form 4?

Joshua B. Cohen reported equity award acquisitions, not open-market trades. He received 248,865 shares of Amylyx common stock through a restricted stock unit grant and a stock option covering 373,295 shares, both subject to multi-year vesting tied to his continued service.

How many restricted stock units did Joshua B. Cohen receive from Amylyx (AMLX)?

He received a restricted stock unit award for 248,865 shares of Amylyx common stock. These RSUs will vest in four equal annual installments, beginning on March 1, 2027, provided he continues to serve the company through each scheduled vesting date.

What stock option grant did Amylyx (AMLX) report for Co-CEO Joshua B. Cohen?

Amylyx reported granting Joshua B. Cohen a stock option for 373,295 shares. Twenty-five percent of the option vests on March 1, 2027, with the remaining shares vesting monthly over the next 36 months, conditioned on his continuous service with the company.

When do Joshua B. Cohen’s Amylyx (AMLX) restricted stock units vest?

The restricted stock units begin vesting on March 1, 2027. They vest in four equal annual installments on that date and on each of the next three anniversaries, assuming Joshua B. Cohen remains in service with Amylyx through each vesting date.

What is the vesting schedule for Joshua B. Cohen’s new Amylyx stock options?

For the 373,295-share option grant, 25% vests on March 1, 2027. The remaining 75% then vests in equal monthly installments over the following 36 months, contingent on Joshua B. Cohen’s continuous service to Amylyx Pharmaceuticals throughout the vesting period.

Did Joshua B. Cohen buy or sell Amylyx (AMLX) shares on the market in this filing?

The filing shows equity awards being granted, not market purchases or sales. Transactions coded as grants include a restricted stock unit award and a stock option, both awarded at a reported price of $0.0000 per share, reflecting compensation rather than open-market trading.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 04:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Joshua B

(Last) (First) (Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		A		248,865(1)	A	$0	3,583,548	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.1	03/05/2026		A		373,295		(2)	03/05/2036	Common Stock	373,295	$0	373,295	D

Explanation of Responses:

1. The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

2. 25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

	/s/ Joshua B. Cohen	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.